PatentsChina
China’s Supreme People’s Court Defines Profit-Based Criteria for Inventor Compensation in Biosimilar Patent Dispute
In a pivotal decision, China’s Supreme People’s Court resolved a dispute over inventor remuneration tied to a patented biosimilar adalimumab formulation. The court established that remuneration is owed based on annual operating profits generated by the patented invention’s commercial implementation, regardless of the…
Wednesday, September 16, 2026